Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

United Therapeutic (UTHR)

United Therapeutic (UTHR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,683,098
  • Shares Outstanding, K 45,300
  • Annual Sales, $ 1,686 M
  • Annual Income, $ 475,800 K
  • 60-Month Beta 0.64
  • Price/Sales 6.04
  • Price/Cash Flow 19.26
  • Price/Book 2.44
Trade UTHR with:

Options Overview Details

View History
  • Implied Volatility 32.80% ( -2.47%)
  • Historical Volatility 48.14%
  • IV Percentile 21%
  • IV Rank 16.33%
  • IV High 62.13% on 10/15/21
  • IV Low 27.07% on 01/31/22
  • Put/Call Vol Ratio 0.50
  • Today's Volume 1,006
  • Volume Avg (30-Day) 343
  • Put/Call OI Ratio 0.92
  • Today's Open Interest 8,468
  • Open Int (30-Day) 10,981

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate 3.98
  • Number of Estimates 5
  • High Estimate 4.35
  • Low Estimate 3.42
  • Prior Year 3.65
  • Growth Rate Est. (year over year) +9.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
174.36 +35.25%
on 05/10/22
236.06 -0.10%
on 05/27/22
+58.53 (+33.01%)
since 04/27/22
3-Month
158.38 +48.90%
on 03/11/22
236.06 -0.10%
on 05/27/22
+67.83 (+40.38%)
since 02/25/22
52-Week
158.38 +48.90%
on 03/11/22
236.06 -0.10%
on 05/27/22
+50.09 (+26.97%)
since 05/27/21

Most Recent Stories

More News
Why Liquidia Stock Rose as Much as 22% Higher Today

A major bank initiated coverage of the stock with a very bullish recommendation and price target.

BAC : 37.02 (+0.95%)
LQDA : 4.07 (+0.99%)
UTHR : 235.83 (+4.92%)
United Therapeutics (UTHR) Gains on Tyvaso DPI Approval

The FDA approves United Therapeutics' (UTHR) drug-device combination therapy, Tyvaso DPI, for PAH patients. It is a dry-powder inhalation formulation of Treprostinil. Stock gains 8.8%.

MNKD : 4.44 (-2.84%)
UTHR : 235.83 (+4.92%)
PRPH : 8.48 (-0.47%)
LQDA : 4.07 (+0.99%)
Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

UTHR : 235.83 (+4.92%)
United Therapeutics Announces FDA Approval of Tyvaso DPI™

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the U.S. Food and Drug Administration ( FDA ) has approved Tyvaso DPI™ (treprostinil) inhalation powder...

UTHR : 235.83 (+4.92%)
United Therapeutics (UTHR) Q1 Earnings & Sales Beat, Stock Up

United Therapeutics' (UTHR) first-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso mainly drive the top line in the quarter.

LLY : 323.48 (+3.20%)
UTHR : 235.83 (+4.92%)
XNCR : 22.69 (+1.48%)
PRPH : 8.48 (-0.47%)
5 Undervalued Stocks to Scoop Up in May

The market selloff caused by the difficult macroeconomic and geopolitical issues has led many quality stocks to now trade below their intrinsic values. Agilent Technologies (A), United Therapeutics (UTHR),...

A : 130.55 (+5.41%)
BHC : 9.87 (+0.10%)
NSANY : 7.8500 (+0.77%)
UTHR : 235.83 (+4.92%)
WIRE : 126.97 (+2.50%)
United Therapeutics (UTHR) Q1 Earnings and Revenues Surpass Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of 69.93% and 12.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

UTHR : 235.83 (+4.92%)
BBI : 0.1595 (+2.05%)
United Therapeutics Corporation Reports First Quarter 2022 Financial Results

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2022. Total revenue in the first quarter of 2022 grew...

UTHR : 235.83 (+4.92%)
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the 2022 American Thoracic Society International Conference

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that eight posters and three mini-symposia across the company’s commercial and development portfolio will...

UTHR : 235.83 (+4.92%)
United Therapeutics (UTHR) to Report Q1 Results: Wall Street Expects Earnings Growth

United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

UTHR : 235.83 (+4.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by...

See More

Key Turning Points

3rd Resistance Point 253.29
2nd Resistance Point 244.68
1st Resistance Point 240.25
Last Price 235.83
1st Support Level 227.21
2nd Support Level 218.60
3rd Support Level 214.17

See More

52-Week High 236.06
Last Price 235.83
Fibonacci 61.8% 206.39
Fibonacci 50% 197.22
Fibonacci 38.2% 188.05
52-Week Low 158.38

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar